North America Novel Drug Delivery Systems (NDDS) Market Size (2024 - 2029)

The North America Novel Drug Delivery Systems market is experiencing growth driven by the increasing demand for controlled drug release and advancements in technology. The need for maintaining optimal drug concentrations in the body, to avoid toxicity or lack of therapeutic benefits, is propelling the market. Systems such as transdermal patches, nasal systems, and microcapsules are key components of this market. However, the market's expansion is challenged by stringent regulatory guidelines and product recalls, which are significant restraining factors.

Market Size of North America Novel Drug Delivery Systems (NDDS) Industry

CAGR
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 5.80 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

North America Novel Drug Delivery Systems Market Analysis

The major factors for the growth of the market include the growing need of controlled release of drugs, and technological advancements promoting the development of NDDS. Most of the drugs have an optimum concentration range and requirement of controlled release of drugs in the body. Concentrations above or below the prescribed range can be toxic or can produce no therapeutic benefits. Transdermal patches, nasal systems, microcapsules, etc., are some of the common systems that are considered under the controlled release systems. Hence, the requirement of the controlled release of drugs drives the novel drug delivery systems market. The stability of a delivery system is one of the most important factors that affect the drug delivery systems market. The restraining factors include stringent regulatory guidelines and product recalls.

North America Novel Drug Delivery Systems Industry Segmentation

As per the scope of this report, the novel drug delivery system (NDDS) is intended to increase the efficacy of drugs. NDDSs are adopted to increase the bioavailability of the drug, to reduce adverse effects and side effects, and increase drug stability. The market is segmented by route of administration, mode of NDDS, and geography.

By Route of Administration
Oral Drug Delivery Systems
Injectable Drug Delivery Systems
Pulmonary Drug Delivery Systems
Transdermal Drug Delivery Systems
Others
By Mode of NDDS
Targeted Drug Delivery Systems
Controlled Drug Delivery Systems
Modulated Drug Delivery Systems
Geography
North America
United States
Canada
Mexico
Need A Different Region Or Segment?
Customize Now

North America Novel Drug Delivery Systems (NDDS) Market Size Summary

The North America Novel Drug Delivery Systems (NDDS) market is experiencing growth driven by the increasing demand for controlled drug release mechanisms and advancements in technology. These systems, which include transdermal patches, nasal systems, and microcapsules, are essential for maintaining drug concentrations within therapeutic ranges, as deviations can lead to toxicity or lack of efficacy. The stability of these delivery systems is crucial for their success in the market. However, the industry faces challenges such as stringent regulatory guidelines and the potential for product recalls, which can hinder market expansion.

Oral drug delivery remains the most favored method of administration due to its high patient compliance, cost-effectiveness, and ease of production. This method is particularly driven by the rising incidence of chronic diseases and significant investments by major pharmaceutical companies in developing advanced oral delivery technologies. Key players in the market, including Abbott Laboratories, AstraZeneca, Bayer AG, and others, are focusing on innovative treatment options to capture a larger market share. These companies are actively engaged in reformulating and repositioning drugs to enhance their oral delivery systems, further propelling market growth.

Explore More

North America Novel Drug Delivery Systems (NDDS) Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Need of Controlled Release of Drugs

      2. 1.2.2 Technological Advancements Promoting Development of NDDS

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Guidelines and Product Recalls

      2. 1.3.2 Stability Issues of the Devices

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Route of Administration

      1. 2.1.1 Oral Drug Delivery Systems

      2. 2.1.2 Injectable Drug Delivery Systems

      3. 2.1.3 Pulmonary Drug Delivery Systems

      4. 2.1.4 Transdermal Drug Delivery Systems

      5. 2.1.5 Others

    2. 2.2 By Mode of NDDS

      1. 2.2.1 Targeted Drug Delivery Systems

      2. 2.2.2 Controlled Drug Delivery Systems

      3. 2.2.3 Modulated Drug Delivery Systems

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

North America Novel Drug Delivery Systems (NDDS) Market Size FAQs

The North America Novel Drug Delivery Systems (NDDS) Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)

Abbott Laboratories, Roche Holding AG, Merck & Co., GlaxoSmithKline PLC and Bayer AG are the major companies operating in the North America Novel Drug Delivery Systems (NDDS) Market.

North America Novel Drug Delivery Systems Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)